Skin external preparation containing loxoprofen and solubilizer

By adding polysorbate 60 or 80 to loxoprofen-based skin preparations with tocopherol acetate and l-menthol, the formulation significantly enhances transdermal absorption and analgesic/anti-inflammatory effects, addressing the lack of effective percutaneous absorption in existing loxoprofen preparations.

JP2024163305AActive Publication Date: 2024-11-21DAIICHI SANKYO HEALTHCARE
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2024158687
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-03-25
Filing Date
2024-09-13
Publication Date
2024-11-21
Estimated Expiration
2040-03-24

AI Technical Summary

Technical Problem

Existing external preparations containing loxoprofen do not effectively enhance percutaneous absorption, despite the inclusion of ingredients like tocopherol acetate and l-menthol, and the role of solubilizers in this context remains unclear.

Method used

Incorporating polysorbate, specifically polysorbate 60 or polysorbate 80, into the external skin preparation along with loxoprofen, tocopherol acetate, and l-menthol significantly enhances transdermal absorbability.

Benefits of technology

The formulation achieves improved usability, enhanced transdermal absorption, and excellent analgesic and anti-inflammatory properties with a blood circulation promoting effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163305000001
    Figure 2024163305000001
  • Figure 2024163305000002
    Figure 2024163305000002
  • Figure 2024163305000003
    Figure 2024163305000003
Patent Text Reader

Abstract

To provide a skin external preparation (compounding agent) containing loxoprofen and other active ingredients, the skin external preparation having further improved percutaneous absorbency of loxoprofen.SOLUTION: A skin external preparation contains loxoprofen or a salt thereof, l-menthol, ethanol, tocopherol or a derivative thereof and polysorbate.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a skin preparation containing loxoprofen, which has excellent analgesic and anti-inflammatory effects. More specifically, the present invention relates to a skin preparation having significantly improved percutaneous absorbability compared to conventional loxoprofen preparations and their formulation techniques by incorporating a specific solubilizing agent into loxoprofen. [Background technology]

[0002] Loxoprofen, a propionic acid-based nonsteroidal antipyretic, analgesic, and anti-inflammatory drug (NSAID), has antipyretic, analgesic, and anti-inflammatory effects based on the inhibition of prostaglandin biosynthesis, similar to other NSAIDs. Loxoprofen is a prodrug that is absorbed from the digestive tract as an unchanged form with weak gastric mucosa irritation after oral administration and becomes an active form in the body, and is therefore known to have the characteristic of causing less gastric mucosa damage than the active form (see, for example, Non-Patent Document 1).

[0003] In recent years, loxoprofen has been commercially available as a topical anti-inflammatory analgesic agent in the form of poultices, tapes and gels, and has been used in clinical trials (see, for example, Non-Patent Document 2). It is known that loxoprofen is also converted to the trans-OH form (active form) by ketone reductase in the skin (see, for example, Patent Document 1).

[0004] l-Menthol is used as a blood circulation promoter in topical preparations, and as a cooling agent and fragrance in pharmaceutical additives. Tocopherol acetate is used as a blood circulation promoter in topical preparations, and as a stabilizer and antioxidant in pharmaceutical additives.

[0005] In topical preparations, polysorbates are used as stabilizers, surfactants, solubilizers, bases, suspending agents, wetting agents, antifoaming agents, emulsifiers, thickening agents, dispersants, dissolving agents, and solubilizing agents.

[0006] It has been disclosed that the percutaneous absorption of loxoprofen is enhanced by blending carboxyvinyl polymer, propylene glycol, and propylene glycol fatty acid ester as additives in topical preparations containing loxoprofen (see Patent Documents 2 and 3). In addition, polyhydric alcohols such as propylene glycol, butylene glycol, and glycerin are often added to improve the feeling of use of topical liquid preparations for the skin, and it is known that these polyhydric alcohols are used as percutaneous absorption enhancers of medicinal ingredients (see Patent Document 4). It is also known that antihistamines enhance the skin permeability of nonsteroidal anti-inflammatory analgesics and increase the pharmacological effect of the main ingredient (see Patent Document 5). It is also known that the addition of polyoxyethylene hydrogenated castor oil prevents the formation of precipitation or precipitate under acidic conditions (see Patent Document 6).

[0007] Furthermore, an external skin preparation containing loxoprofen and isopropanol is also known (see Patent Document 7).

[0008] However, in topical preparations containing loxoprofen, tocopherol acetate, 1-menthol and ethanol, it is not known at all how the solubilizer affects the percutaneous absorbability of loxoprofen. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] JP2008-074873A [Patent Document 2] Patent No. 4195178 [Patent Document 3] JP2016-79180A [Patent Document 4] Japanese Patent Application Publication No. 5-000946 [Patent Document 5] JP 2002-128698 A [Patent Document 6] Patent No. 6131522 [Patent Document 7] JP 2017-200909 A [Non-patent literature]

[0010] [Non-Patent Document 1] Pharmacology and Treatment Vol.16 No.2 1988 p.611-619 [Non-Patent Document 2] JAPIC Medical Pharmaceuticals Collection 2013 Maruzen 2012 Summary of the Invention [Problem to be solved by the invention]

[0011] An object of the present invention is to provide an external preparation for the skin (combination preparation) containing loxoprofen and other active ingredients, which has improved percutaneous absorbability of loxoprofen. [Means for solving the problem]

[0012] The present inventors have studied ingredients to be added to solubilize the active ingredients of a topical preparation containing loxoprofen, in order to develop a topical preparation (combination preparation) further containing ingredients such as tocopherol acetate and l-menthol for the purpose of promoting blood circulation. As a result, it was found that when polyoxyethylene hydrogenated castor oil is added to a topical preparation containing loxoprofen, tocopherol acetate, ethanol and l-menthol, the appearance is improved compared to when polyoxyethylene hydrogenated castor oil is not added, but the skin permeability is reduced. Therefore, it was found that the percutaneous absorbability of loxoprofen is significantly increased when polyoxyethylene hydrogenated castor oil is added instead of polyoxyethylene hydrogenated castor oil, and the present invention was completed.

[0013] That is, according to the present invention, the following inventions are provided. (1) A skin preparation for topical application containing loxoprofen or its salt, l-menthol, ethanol, tocopherol or its derivative, and polysorbate. (2) The topical skin preparation according to (1), wherein the polysorbate is one or more selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65 and polysorbate 80. (3) The topical skin preparation described in (1), wherein the polysorbate is polysorbate 60 or polysorbate 80. (4) The topical skin preparation according to any one of (1) to (3), wherein the content of the polysorbate in the topical skin preparation is 0.2 to 18% by weight. (5) The external skin preparation according to any one of (1) to (4), wherein the tocopherol or a derivative thereof is tocopherol acetate. (6) The topical skin preparation according to any one of (1) to (5), wherein the pH of the topical skin preparation is 4.0 to 12.0. (7) The external skin preparation according to any one of (1) to (6), which is for analgesic and anti-inflammatory purposes. (8) The external skin preparation according to any one of (1) to (7), which has a dosage form of an external liquid preparation, an ointment, a cream, a spray, a gel, a patch, or a solid preparation for external use. (9) The external skin preparation according to any one of (1) to (7), which has a dosage form of an external liquid preparation. Effect of the Invention

[0014] The topical skin preparation of the present invention containing rofecoxib or a salt thereof, l-menthol, ethanol, tocopherol or a derivative thereof, and polysorbate is extremely useful clinically because it has an excellent feel when used, enhances the percutaneous absorption of rofecoxib, and has excellent anti-inflammatory and analgesic effects and blood circulation promoting effects. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] In the present invention, "loxoprofen or a salt thereof" includes loxoprofen or a salt thereof, as well as hydrates thereof. As the salt of loxoprofen, a pharmacologically acceptable salt is preferred, more preferably loxoprofen sodium or loxoprofen sodium dihydrate, and even more preferably loxoprofen sodium dihydrate. In this specification, the term loxoprofen includes loxoprofen or a salt thereof, as well as hydrates thereof.

[0016] The loxoprofen in the present invention is listed in the 17th edition of the Japanese Pharmacopoeia as loxoprofen sodium hydrate.

[0017] The l-menthol used in the present invention is listed in the 17th revised Japanese Pharmacopoeia and the Pharmaceutical Additives Encyclopedia 2016 (Yakuji Nipposha, 2016).

[0018] Examples of tocopherol or its derivatives in the present invention include tocopherol, d-δ-tocopherol, tocopherol acetate, etc., and preferably tocopherol acetate. Tocopherol, d-δ-tocopherol, and tocopherol acetate are listed in the 17th revised Japanese Pharmacopoeia and the Pharmaceutical Additives Dictionary 2016.

[0019] The skin external preparation of the present invention may contain polyhydric alcohol. The polyhydric alcohol in the present invention is an alcohol having two or more hydroxyl groups in the molecule, which is used in external preparations for purposes such as solubilizers, bases, moisturizers, thickeners, solvents, and dissolution aids, and is, for example, propylene glycol, 1,3-butylene glycol, macrogol (also called polyethylene glycol), and D-sorbitol, and is listed in the Pharmaceutical Additives Encyclopedia 2016.

[0020] The ethanol (also called ethyl alcohol) in the skin external preparation of the present invention is used in external preparations as a solubilizer, base, solvent, dissolution aid, and examples thereof include ethanol, absolute ethanol, etc. The ethanol and absolute ethanol in the present invention are listed in the Pharmaceutical Additives Encyclopedia 2016.

[0021] Examples of the polysorbate in the external skin preparation of the present invention include polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, etc., with polysorbate 60 or polysorbate 80 being preferred.

[0022] The content of loxoprofen in the external skin preparation of the present invention is preferably 0.1 to 10% by weight, and more preferably 0.5 to 8.5% by weight, calculated as loxoprofen sodium dihydrate. The content of l-menthol in the external skin preparation of the present invention is preferably 0.01 to 10% by weight, and more preferably 0.5 to 7.5% by weight. The content of tocopherol or a derivative thereof in the external skin preparation of the present invention is usually 0.001 to 5% by weight, preferably 0.05 to 3% by weight, and more preferably 0.1 to 1% by weight. The content of polysorbate in the external skin preparation of the present invention is 0.2 to 18% by weight, preferably 0.5 to 15% by weight, and more preferably 1.0 to 12% by weight. Furthermore, the blending ratio of tocopherol or a derivative thereof to polysorbate in the present invention is preferably 2 parts by weight or more, and more preferably 5 parts by weight or more, of polysorbate per 1 part by weight of tocopherol or a derivative thereof.

[0023] Furthermore, the range of the amount of ethanol added to the external skin preparation of the present invention is not particularly limited, but is preferably 10.0 to 70.0% by weight, and more preferably 30.0 to 60.0%. Furthermore, when a polyhydric alcohol is added, the amount of the polyhydric alcohol added is not particularly limited, but is preferably 0.5 to 20%, more preferably 1.0 to 15%.

[0024] The pH range of the external skin preparation is preferably 4.0 to 12.0, more preferably 4.0 to 8.0, even more preferably 5.0 to 7.5, and most preferably 6.0 to 7.5.

[0025] The skin external preparation of the present invention may contain drugs and pharmaceutical additives other than the above-mentioned ingredients that are commonly used in analgesic and anti-inflammatory skin external preparations. Examples of such drugs include anti-inflammatory drugs such as glycyrrhetinic acid, antihistamines such as chlorpheniramine maleate, blood circulation improving ingredients such as nicotinic acid benzyl ester, local stimulating ingredients such as capsicum extract and nonanoic acid vanillylamide, herbal medicine ingredients such as arnica tincture, etc. These drugs can be blended within a range that does not impair the effects of the present invention.

[0026] Pharmaceutical additives other than the above-mentioned components are added as necessary, for example, for the purpose of further improving the stability of the content over time and the feeling of use, and examples of such additives include humectants, pH adjusters, antioxidants, and cooling agents. As such a wetting agent, for example, sodium dl-pyrrolidone carboxylate or the like can be added. Examples of the pH regulator that can be used include hydrochloric acid, sodium hydroxide, potassium hydroxide, phosphoric acid, organic acids such as lactic acid, and organic amines such as triethanolamine. Examples of antioxidants that can be used include ascorbic acid, ascorbic acid palmitate, sodium hydrogen sulfite, sodium pyrosulfite, sodium edetate, citric acid hydrate, anhydrous citric acid, dibutylhydroxytoluene, butylhydroxyanisole, benzotriazole, and propyl gallate. Examples of the freshening agent include camphor, dl-camphor, peppermint oil, eucalyptus oil, and the like.

[0027] Specific examples of the dosage form of the skin topical preparation of the present invention include liquid for external use, ointment, cream, spray (aerosol for external use, pump spray), gel, patch (tape, cataplasm), or solid for external use, and each dosage form can be produced by appropriately using additives and bases suitable for the dosage form, according to the usual method described in the 17th edition of the Japanese Pharmacopoeia, etc. The dosage form of the skin topical preparation of the present invention is preferably liquid for external use or gel, and more preferably liquid for external use. The skin topical preparation of the present invention can be stored and sealed in a container or package made of a metal such as aluminum, or an olefin resin such as polyethylene or polypropylene. Such a container may be a bottle container or a roll-on container equipped with a sponge-like application member, which has been widely used in the past. The material of the sponge-like application member may be an olefin resin such as polyethylene or polyurethane.

[0028] The skin external preparation of the present invention can be used as an analgesic and anti-inflammatory agent for patients with pain or inflammation, such as patients with lower back pain, bruises, sprains, shoulder pain associated with stiff shoulders, tendonitis, elbow pain, arthralgia, etc. The skin external preparation of the present invention is applied, sprayed or pasted in an appropriate amount onto the affected area by the patient once to several times a day. The present invention will now be described in more detail with reference to examples. EXAMPLES

[0029] (Test Example 1) Skin permeability test 1 of topical skin preparation containing loxoprofen (1) Preparation of test materials and specimens The following products were used: loxoprofen sodium dihydrate manufactured by Daiichi Sankyo Chemical Pharma Co., Ltd., tocopherol acetate manufactured by Riken Vitamin Co., Ltd., l-menthol manufactured by Suzuki Mint Co., Ltd., polyoxyethylene hydrogenated castor oil 60 manufactured by Nikko Chemicals Co., Ltd., hydrochloric acid manufactured by Kanto Chemical Co., Ltd., propylene glycol manufactured by Maruishi Pharmaceutical Co., Ltd., and absolute ethanol manufactured by Imazu Pharmaceutical Co., Ltd. The components listed in Table 1 below were mixed and dissolved to obtain liquid preparations of samples 1 and 2. The pH of both samples 1 and 2 was adjusted to 6.5.

[0030] (2) Test method Reconstructed human epidermis model (EPISKIN large, effective diffusion area 1.07 cm 2 A 12-well tissue culture plate (IWAKI, Asahi Glass Co., Ltd.) was placed in the well, and 2 mL of 1 / 15 M phosphate buffered saline (pH 7.4) (PBS) was dispensed into each well to serve as the receiver solution. 200 μL of each specimen was placed on the donor side, and the tissue culture plate was covered with a lid and placed in an incubator at 32°C to conduct the skin permeability test. The receiver solution after permeation was collected, and the concentration of loxoprofen sodium in the receiver solution was measured by high performance liquid chromatography (HPLC) to calculate the amount of loxoprofen sodium permeated per unit area. The test was performed three times for each specimen, and the average value was calculated. From the value, the relative permeation amount was calculated when the cumulative amount of loxoprofen sodium per unit area of ​​the control (specimen 1) 2 hours after permeation was taken as 100.

[0031] (3) Check the appearance The appearance (transparency, precipitate) of each liquid formulation obtained was visually inspected immediately after production. Transparency was rated on a four-level scale of A, B, C, and D, with only A being in the acceptable range. Precipitates were evaluated on a two-level scale: -: no precipitate, +: precipitate present, with only - being considered within the acceptable range.

[0032] The quantitative determination of loxoprofen sodium was performed by liquid chromatography under the following conditions. Detector: ultraviolet absorption spectrophotometer (measurement wavelength: 210 nm), column: 4.6 mm inner diameter, 15 cm long stainless steel packed with 5 μm octadecylsilylated silica gel for liquid chromatography, column temperature: 40°C, mobile phase: methanol / water / phosphoric acid (550: 450: 1)

[0033] (4) Test results The results are shown in Table 1.

[0034] [Table 1]

[0035] The amount of rofecoxib sodium hydrate is equivalent to 1 g of rofecoxib sodium (anhydrous equivalent).

[0036] A comparison of sample 1 and sample 2 in Table 1 shows that in a topical preparation (combination preparation) containing rofecoxib, l-menthol, tocopherol acetate, and absolute ethanol, when polyoxyethylene hydrogenated castor oil 60 was added as a surfactant, the transparency of the appearance was improved compared to when no polyoxyethylene hydrogenated castor oil 60 was added, but the amount of skin penetration was significantly reduced.

[0037] (Test Example 2) Skin permeability test 2 of topical skin preparation containing loxoprofen (1) Preparation of test materials and specimens The loxoprofen sodium dihydrate used was manufactured by KOLON Co., Ltd., the tocopherol acetate was manufactured by Eisai Food Chemical Co., Ltd., and the 1,3-butylene glycol was manufactured by Kanto Chemical Co., Ltd. The l-menthol, polyoxyethylene hydrogenated castor oil 60, hydrochloric acid, and absolute ethanol used were the same as those used in Test Example 1. The components listed in Table 2 below were mixed and dissolved to obtain liquid preparations of samples 3 and 4. The pH of samples 3 and 4 was adjusted to 6.5.

[0038] (2) Test method Reconstructed human epidermis model (EPISKIN large, effective diffusion area 1.07 cm 2 A 12-well tissue culture plate (IWAKI, Asahi Glass Co., Ltd.) was placed on the well and a skin permeability test was carried out in the same manner as in Test Example 1. The receiver solution after permeation was collected and the concentration of loxoprofen sodium in the receiver solution was measured by high performance liquid chromatography (HPLC) to calculate the amount of loxoprofen sodium permeated per unit area. The test was carried out three times for each specimen, and the average value was calculated. From this value, the relative permeation amount was calculated when the cumulative amount of loxoprofen sodium per unit area of ​​the control (specimen 4) 2 hours after permeation was taken as 100.

[0039] (3) Check the appearance Immediately after production, the appearance (transparency, precipitate) of each of the obtained liquid preparations was visually confirmed in the same manner as in Test Example 1.

[0040] The amount of loxoprofen sodium was determined in the same manner as in Test Example 1.

[0041] (4) Test results The results are shown in Table 2.

[0042] [Table 2]

[0043] The amount of rofecoxib sodium hydrate is equivalent to 1 g of rofecoxib sodium (anhydrous equivalent).

[0044] A comparison of sample 3 and sample 4 in Table 2 revealed that in a topical preparation (combination preparation) containing rofecoxib, l-menthol, tocopherol acetate, and absolute ethanol, when no surfactant was added, the preparation became cloudy and a precipitate formed, whereas when polyoxyethylene hydrogenated castor oil 60 was added as a surfactant, the transparency of the appearance was improved, but the percutaneous absorption of rofecoxib decreased.

[0045] (Test Example 3) Skin permeability test 3 of topical skin preparation containing loxoprofen (1) Preparation of test materials and specimens The same loxoprofen sodium dihydrate, tocopherol acetate, l-menthol, polyoxyethylene hydrogenated castor oil, hydrochloric acid, 1,3-butylene glycol and absolute ethanol were used as in Test Example 2, and polysorbate 60 and polysorbate 80 were manufactured by Nikko Chemicals Co., Ltd. The components shown in Table 3 below were mixed and dissolved to obtain liquid preparations of samples 4 to 6. The pH of samples 4 to 6 was adjusted to 6.5.

[0046] (2) Test method Reconstructed human epidermis model (EPISKIN large, effective diffusion area 1.07 cm 2 A 12-well tissue culture plate (IWAKI, Asahi Glass Co., Ltd.) was placed on the well and a skin permeability test was carried out in the same manner as in Test Example 1. The receiver solution after permeation was collected and the concentration of loxoprofen sodium in the receiver solution was measured by high performance liquid chromatography (HPLC) to calculate the amount of loxoprofen sodium permeated per unit area. The test was carried out three times for each specimen, and the average value was calculated. From this value, the relative permeation amount was calculated when the cumulative amount of loxoprofen sodium per unit area of ​​the control (specimen 4) 2 hours after permeation was taken as 100.

[0047] (3) Check the appearance Immediately after production, the appearance (transparency, precipitate) of each of the obtained liquid preparations was visually confirmed in the same manner as in Test Example 1.

[0048] The amount of loxoprofen sodium was determined in the same manner as in Test Example 1.

[0049] (4) Test results The results are shown in Table 3.

[0050] [Table 3]

[0051] The amount of rofecoxib sodium hydrate is equivalent to 1 g of rofecoxib sodium (anhydrous equivalent).

[0052] By comparing Sample 4 with Samples 5 and 6 in Table 3, it was found that in a topical preparation (combination preparation) containing loxoprofen, l-menthol, tocopherol acetate and absolute ethanol, the percutaneous absorption of loxoprofen was increased when polysorbate 60 or polysorbate 80 was blended as a surfactant, compared to when polyoxyethylene hydrogenated castor oil 60 was blended. The appearance of Samples 4, 5 and 6 immediately after production was good.

[0053] (Test Example 4) Skin permeability test 4 of topical skin preparation containing loxoprofen (1) Preparation of test materials and specimens The same ingredients as in Test Example 1 were used for loxoprofen sodium dihydrate, tocopherol acetate, l-menthol, polyoxyethylene hydrogenated castor oil 60, hydrochloric acid, propylene glycol, and absolute ethanol, and the same polysorbate 80 as in Test Example 3. The ingredients listed in Table 4 below were mixed and dissolved to obtain liquid preparations of samples 7 and 8. The pH of samples 7 and 8 was adjusted to 6.5.

[0054] (2) Test method Reconstructed human epidermis model (EPISKIN large, effective diffusion area 1.07 cm 2 A 12-well tissue culture plate (IWAKI, Asahi Glass Co., Ltd.) was placed on the well and a skin permeability test was carried out in the same manner as in Test Example 1. The receiver solution after permeation was collected and the concentration of loxoprofen sodium in the receiver solution was measured by high performance liquid chromatography (HPLC) to calculate the amount of loxoprofen sodium permeated per unit area. The test was carried out three times for each specimen, and the average value was calculated. From this value, the relative permeation amount was calculated when the cumulative amount of loxoprofen sodium per unit area of ​​the control (specimen 7) 2 hours after permeation was taken as 100.

[0055] (3) Check the appearance Immediately after production, the appearance (transparency, precipitate) of each of the obtained liquid preparations was visually confirmed in the same manner as in Test Example 1.

[0056] The amount of loxoprofen sodium was determined in the same manner as in Test Example 1.

[0057] (4) Test results The results are shown in Table 4. [Table 4]

[0058] Comparing sample 7 and sample 8 in Table 3, it was found that in a topical preparation (combination preparation) containing loxoprofen, l-menthol, tocopherol acetate, and absolute ethanol, even when the amount of tocopherol was reduced, the inclusion of polysorbate 80 as a surfactant increased the percutaneous absorption of loxoprofen compared to the inclusion of polyoxyethylene hydrogenated castor oil 60. Both samples 7 and 8 had good appearance immediately after production.

[0059] (Formulation example) After dissolving the components shown in the following Tables 5 and 6 by stirring and mixing, the skin topical preparations of Formulation Examples 1 to 22 can be obtained. The preparation can be produced by taking the above-mentioned ingredients and amounts and following the procedures prescribed in the General Provisions for Preparations in the Japanese Pharmacopoeia, Sections on "External Solutions" and "Gels".

[0060] Table 5: Topical solutions [Table 5] JPEG2024163305000006.jpg128170

[0061] *Equivalent to 1g of rofecoxib sodium (anhydrous equivalent).

[0062] Table 6: Gels [Table 6] JPEG2024163305000008.jpg138170

[0063] *Equivalent to 1g of rofecoxib sodium (anhydrous equivalent). [Industrial Applicability]

[0064] The topical skin preparation containing loxoprofen of the present invention is extremely useful since it provides an excellent feeling when used, enhances the percutaneous absorption of loxoprofen, and has excellent anti-inflammatory and analgesic effects and blood circulation promoting effects.

Claims

1. A method for improving the skin permeability of an external skin preparation containing loxoprofen or a salt thereof, the method comprising combining loxoprofen or a salt thereof, 1-menthol, ethanol, tocopherol or a derivative thereof, and polysorbate.

2. 2. The method for improving skin permeability according to claim 1, wherein the polysorbate is one or more selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65 and polysorbate 80.

3. The method for improving skin permeability according to claim 1 , wherein the polysorbate is polysorbate 60 or polysorbate 80.

4. The method for improving skin permeability according to any one of claims 1 to 3, wherein the content of polysorbate in the topical skin preparation is 0.2 to 18 wt%.

5. The method for improving skin permeability according to any one of claims 1 to 4, wherein the tocopherol or a derivative thereof is tocopherol acetate.

6. The method for improving skin permeability according to any one of claims 1 to 5, wherein the pH of the topical skin preparation is 4.0 to 12.

0.

7. The method for improving skin permeability according to any one of claims 1 to 6, wherein the skin topical preparation is for analgesic and anti-inflammatory purposes.

8. The method for improving skin permeability according to any one of claims 1 to 7, wherein the dosage form of the external skin preparation is an external liquid preparation, an ointment, a cream, a spray preparation, a gel preparation, a patch, or an external solid preparation.

9. The method for improving skin permeability according to any one of claims 1 to 7, wherein the dosage form of the topical skin preparation is a liquid preparation for topical application.

10. The method for improving skin permeability according to any one of claims 1 to 9, wherein the external skin preparation is contained in a container made of an olefin-based resin.

Citation Information

Patent Citations

  • Semisolid preparation comprising ketoprofen and preparation method thereof

    CN109303762A

  • Loxoprofen-containing aerosol composition

    JP2012193173A

  • Pharmaceutical preparation containing loxoprofen

    JP2018021002A

  • Joint member for underground continuous wall and manufacture thereof

    JP1986031522A

  • Ketotifen-containing percutaneous absorption preparation

    JP1993000946A